Cis-Diamminedichloroplatinum Ii
Ureter Transitional Cell Carcinoma
Explore 15 assets in Ureter Transitional Cell Carcinoma →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ureter Transitional Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cis-Diamminedichloroplatinum Ii (this asset) | National Cancer Institute (NCI) | P3 | B · 62 |
| Nivolumab | Alliance for Clinical Trials in Oncology | P3 | BB |
| Cyclophosphamide | Fred Hutchinson Cancer Center | P3 | BB |
| Pembrolizumab | Fred Hutchinson Cancer Center | P3 | BB |
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) | Fred Hutchinson Cancer Center | P2 | BB |
| Atezolizumab | Alliance for Clinical Trials in Oncology | P3 | B |
| Relatlimab | M.D. Anderson Cancer Center | P2 | B |
| Durvalumab | Alliance for Clinical Trials in Oncology | P3 | B |
| Ipilimumab | M.D. Anderson Cancer Center | P2 | B |
+11 more in the Ureter Transitional Cell Carcinoma cohort
Other indications for Cis-Diamminedichloroplatinum Ii
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Squamous Cell Lung Carcinoma | — | P4 | BBB · 78 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 77 |
| Adenocarcinoma | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- NivolumabAlliance for Clinical Trials in OncologyBB
- CyclophosphamideFred Hutchinson Cancer CenterBB
- PembrolizumabFred Hutchinson Cancer CenterBB
- Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Fred Hutchinson Cancer CenterBB
- AtezolizumabAlliance for Clinical Trials in OncologyB
Citation
Floatz Terminal. Cis-Diamminedichloroplatinum Ii in Ureter Transitional Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cis-diamminedichloroplatinum-ii-ureter-transitional-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →